177Lu-PSMA-617 Archives - Medical Conferences

Baseline ctDNA has both prognostic and predictive value in mCRPC

Presented By

Prof. Johann de Bono, Royal Marsden Hospital, UK

Trial

Phase 3, PSMAfore

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:44

177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC

Presented By

Prof. Michael Hofman, Peter McCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:08

177Lu-PSMA-617: A new class of effective therapy

Presented By

Prof. Johann de Bono; Prof. Michael Hofman

Trial

VISION, TheraP

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:15

VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC

Presented By

Dr Michael Morris, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, VISION

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:18

Lu177 as a promising new therapy for metastatic prostate cancer

Presented By

Dr Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel

Expert

Prof. Michael S. Hofman, Peter MacCallum Cancer Centre, Australia

Trial

TheraP

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 13:54